USFDA gives tentative approval to Lupin’s Dolutegravir and Rilpivirine tablets

The tablets are used to treat HIV infection

The United States Food and Drug Administration (USFDA) has given tentative approval to Lupin for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine tablets, 50 mg/25 mg, to market a generic equivalent of Juluca tablets, 50 mg/25 mg of ViiV Healthcare, a statement from the company notified yesterday.

The tablets are used to treat HIV infection.

 

Dolutegravir and Rilpivirine tabletsHIV treatment tabletsJuluca tabletsLupinUSFDA tentative approval
Comments (2)
Add Comment
  • soundos

    thanks for Sharing this helpful blog.

  • djamila_st

    Hello, I have browsed most of your posts. This post is probably where I got the most useful information for my research. Thanks for posting, maybe we can see more on this. Are you aware of any other websites on this subject